#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Uveitis Acute myeloid leukaemia recurrent Acute graft versus host disease in skin Acute graft versus host disease Asthma Heritable pulmonary arterial hypertension Cardiac arrest Congenital disorder of glycosylation Ventricular fibrillation Nodal marginal zone B-cell lymphoma Anal fistula Breast cancer metastatic White matter lesion Pneumonia Acquired ATTR amyloidosis More trials…

    Learn about Rare Diseases

    Primary mediastinal large B-cell lymphoma – Diagnostics Lymphangioma – Diagnostics Aicardi-Goutieres syndrome – Life with Disease Sjogren’s syndrome – Trials in Disease Thrombotic thrombocytopenic purpura – Basic Information Vascular malformation – Trials in Disease Immunodeficiency congenital – Life with Disease Glomerulonephritis membranoproliferative – Basic Information Skin angiosarcoma – Treatment Nodal marginal zone B-cell lymphoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mva-209-Fsp-B1 Zagociguat ADMILPARANT Etamsylate Vusolimogene Oderparepvec Giroctocogene Fitelparvovec Ioflupane (123I) Gremubamab Doxylamine Hydrogen Succinate Bi 690517 ORG-129 Desoximetasone Riboflavin Sodium Phosphate BROLUCIZUMAB Lixisenatide Isosorbide Dinitrate Fingolimod Hydrochloride Specific Nucleic Acid Sna-Her2 Benzylpenicillin Sodium MB-CART2219.1 More therapies…

    Learn about Your Condition

    Paraganglion neoplasm Lip and/or oral cavity cancer Bronchiolitis Hand dermatitis Acute respiratory failure Gastric cancer recurrent Frostbite Uterine cancer Torticollis Albuminuria Von Willebrand's disease Laryngeal leukoplakia Pseudomonas infection Pericarditis Anal incontinence More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Sjogren’s syndrome

  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome

    Recruiting

    3 1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Deucravacitinib
    Austria Belgium Bulgaria Finland France Germany +9

  • Study on the Effectiveness of CL-AD-MSC-002 Injections for Dry Mouth in Patients with Sjögren’s Syndrome

    Recruiting

    1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Cl-Ad-Msc-002
    Denmark

  • A study to evaluate the effect of obinutuzumab on removing specific immune cells in the tissues of patients with Sjögren’s syndrome.

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Obinutuzumab
    The Netherlands

  • Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Not recruiting

    3 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Not recruiting

    3 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • Nipocalimab
    Austria Bulgaria Czechia Denmark France Germany +9
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!